INIT Intrinsic Valuation and Fundamental Analysis - Initiator Pharma A/S - Alpha Spread
I

Initiator Pharma A/S
STO:INIT

Watchlist Manager
Initiator Pharma A/S
STO:INIT
Watchlist
Price: 7.35 SEK -2% Market Closed
Market Cap: 388.9m SEK
Have any thoughts about
Initiator Pharma A/S?
Write Note

Intrinsic Value

INIT's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one INIT stock under the Base Case scenario is 11.12 SEK. Compared to the current market price of 7.35 SEK, Initiator Pharma A/S is Undervalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

INIT Intrinsic Value
11.12 SEK
Undervaluation 34%
Intrinsic Value
Price
I
Worst Case
Base Case
Best Case

Valuation Backtest
Initiator Pharma A/S

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling INIT based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about INIT?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Initiator Pharma A/S

Provide an overview of the primary business activities
of Initiator Pharma A/S.

What unique competitive advantages
does Initiator Pharma A/S hold over its rivals?

What risks and challenges
does Initiator Pharma A/S face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Initiator Pharma A/S.

Provide P/S
for Initiator Pharma A/S.

Provide P/E
for Initiator Pharma A/S.

Provide P/OCF
for Initiator Pharma A/S.

Provide P/FCFE
for Initiator Pharma A/S.

Provide P/B
for Initiator Pharma A/S.

Provide EV/S
for Initiator Pharma A/S.

Provide EV/GP
for Initiator Pharma A/S.

Provide EV/EBITDA
for Initiator Pharma A/S.

Provide EV/EBIT
for Initiator Pharma A/S.

Provide EV/OCF
for Initiator Pharma A/S.

Provide EV/FCFF
for Initiator Pharma A/S.

Provide EV/IC
for Initiator Pharma A/S.

Show me price targets
for Initiator Pharma A/S made by professional analysts.

What are the Revenue projections
for Initiator Pharma A/S?

How accurate were the past Revenue estimates
for Initiator Pharma A/S?

What are the Net Income projections
for Initiator Pharma A/S?

How accurate were the past Net Income estimates
for Initiator Pharma A/S?

What are the EPS projections
for Initiator Pharma A/S?

How accurate were the past EPS estimates
for Initiator Pharma A/S?

What are the EBIT projections
for Initiator Pharma A/S?

How accurate were the past EBIT estimates
for Initiator Pharma A/S?

Compare the revenue forecasts
for Initiator Pharma A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Initiator Pharma A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Initiator Pharma A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Initiator Pharma A/S compared to its peers.

Compare the P/E ratios
of Initiator Pharma A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Initiator Pharma A/S with its peers.

Analyze the financial leverage
of Initiator Pharma A/S compared to its main competitors.

Show all profitability ratios
for Initiator Pharma A/S.

Provide ROE
for Initiator Pharma A/S.

Provide ROA
for Initiator Pharma A/S.

Provide ROIC
for Initiator Pharma A/S.

Provide ROCE
for Initiator Pharma A/S.

Provide Gross Margin
for Initiator Pharma A/S.

Provide Operating Margin
for Initiator Pharma A/S.

Provide Net Margin
for Initiator Pharma A/S.

Provide FCF Margin
for Initiator Pharma A/S.

Show all solvency ratios
for Initiator Pharma A/S.

Provide D/E Ratio
for Initiator Pharma A/S.

Provide D/A Ratio
for Initiator Pharma A/S.

Provide Interest Coverage Ratio
for Initiator Pharma A/S.

Provide Altman Z-Score Ratio
for Initiator Pharma A/S.

Provide Quick Ratio
for Initiator Pharma A/S.

Provide Current Ratio
for Initiator Pharma A/S.

Provide Cash Ratio
for Initiator Pharma A/S.

What is the historical Revenue growth
over the last 5 years for Initiator Pharma A/S?

What is the historical Net Income growth
over the last 5 years for Initiator Pharma A/S?

What is the current Free Cash Flow
of Initiator Pharma A/S?

Discuss the annual earnings per share (EPS)
trend over the past five years for Initiator Pharma A/S.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Initiator Pharma A/S

Current Assets 20.2m
Cash & Short-Term Investments 14.5m
Receivables 5.7m
Non-Current Assets 17k
PP&E 17k
Current Liabilities 1.3m
Accounts Payable 314k
Accrued Liabilities 868k
Other Current Liabilities 130k
Efficiency

Earnings Waterfall
Initiator Pharma A/S

Revenue
0 DKK
Operating Expenses
-18m DKK
Operating Income
-18m DKK
Other Expenses
1.1m DKK
Net Income
-16.9m DKK

Free Cash Flow Analysis
Initiator Pharma A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

INIT Profitability Score
Profitability Due Diligence

Initiator Pharma A/S's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Initiator Pharma A/S's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

INIT Solvency Score
Solvency Due Diligence

Initiator Pharma A/S's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Initiator Pharma A/S's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

INIT Price Targets Summary
Initiator Pharma A/S

Wall Street analysts forecast INIT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for INIT is 24.48 SEK with a low forecast of 24.24 SEK and a high forecast of 25.2 SEK.

Lowest
Price Target
24.24 SEK
230% Upside
Average
Price Target
24.48 SEK
233% Upside
Highest
Price Target
25.2 SEK
243% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for INIT?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for INIT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about INIT dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

INIT Price
Initiator Pharma A/S

1M 1M
-5%
6M 6M
-15%
1Y 1Y
-4%
3Y 3Y
-26%
5Y 5Y
+15%
10Y 10Y
+64%
Annual Price Range
7.35
52w Low
7.35
52w High
10.4
Price Metrics
Average Annual Return 8.02%
Standard Deviation of Annual Returns 52.15%
Max Drawdown -60%
Shares Statistics
Market Capitalization 412m SEK
Shares Outstanding 52 918 200
Percentage of Shares Shorted
N/A

Competitive Landscape

Profile

Initiator Pharma A/S

Country

Denmark

Industry

Biotechnology

Market Cap

412m SEK

Dividend Yield

0%

Description

Initiator Pharma A/S is a clinical-stage biotechnology company, which engages in the development of novel therapeutics within the field of mono-amine reuptake transporters targeting central nervous system (CNS)-disorders. The firm focuses on developing drugs for treatment of erectile dysfunction.

Contact

KOEBENHAVN
Co/ COBIS, Ole Maaloeesvej 3
www.initiatorpharma.com

IPO

2017-03-16

Employees

-

Officers

See Also

Discover More
What is the Intrinsic Value of one INIT stock?

The intrinsic value of one INIT stock under the Base Case scenario is 11.12 SEK.

Is INIT stock undervalued or overvalued?

Compared to the current market price of 7.35 SEK, Initiator Pharma A/S is Undervalued by 34%.

Back to Top